Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Inks New Credit Facility with Persistence Capital

NEW YORK (GenomeWeb News) – Warnex today said that it has signed a new credit facility with Persistence Capital Partners, replacing an existing credit facility with Accord Financial.

The new facility provides Warnex with up to C$1.25 million (US$1.23 million) in available funds with an interest rate of 19.75 percent. Warnex said that the new agreement provides it with "substantially greater operational flexibility" than its agreement with Accord, which was signed in late April, around the time it completed the sale of its Analytical Services division to Neopharm Labs. Warnex had used the facility from Accord to repay the entirety of the C$975,947 in principal amount of debentures held by Persistence Capital.

"Warnex appreciates the continued and long-term support of PCP that now provides the financial stability necessary for us to concentrate exclusively on our core Bioanalytical Services business," Warnex Chairman Michael Singer said in a statement.

The Laval, Quebec-based firm also said that Mattie Chinks has advised the board that he is stepping down as a director of the company.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.